Is there an intermediate-risk non-seminoma? Long-term treatment results from a single center

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F14%3AE0104306" target="_blank" >RIV/00843989:_____/14:E0104306 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Is there an intermediate-risk non-seminoma? Long-term treatment results from a single center

Popis výsledku v původním jazyce

Purpose: We retrospectively assessed the treatment results of patients with testicular non-seminoma to evaluate possible predictive and prognostic factors. Methods: 189 patients with testicular non-seminoma treated between 2000 and 2012 were retrospectively evaluated. Treatment was based on orchiectomy plus chemotherapy (bleomycin/etoposide/cisplatin and vinblastine/ifosfamide/ cisplatin); retroperitoneal lymphadenectomy was only performed for residual disease after chemotherapy. The treatment protocolwas updated regularly according to international standards. Overall survival (OS) was evaluated with the Kaplan-Meier method at a significance level of 5% according to stage, Karnofsky performance status (KPS), and chemotherapy dose intensity. Results: OS differed significantly for patients at different TNM stages (p=0.000); however, detailed analysis revealed significantly worse survival only in stage IIIC (10-year OS for IIIC vs IIIA+B, 35 vs 88%, p=0.001), while the difference between

Název v anglickém jazyce

Is there an intermediate-risk non-seminoma? Long-term treatment results from a single center

Popis výsledku anglicky

Purpose: We retrospectively assessed the treatment results of patients with testicular non-seminoma to evaluate possible predictive and prognostic factors. Methods: 189 patients with testicular non-seminoma treated between 2000 and 2012 were retrospectively evaluated. Treatment was based on orchiectomy plus chemotherapy (bleomycin/etoposide/cisplatin and vinblastine/ifosfamide/ cisplatin); retroperitoneal lymphadenectomy was only performed for residual disease after chemotherapy. The treatment protocolwas updated regularly according to international standards. Overall survival (OS) was evaluated with the Kaplan-Meier method at a significance level of 5% according to stage, Karnofsky performance status (KPS), and chemotherapy dose intensity. Results: OS differed significantly for patients at different TNM stages (p=0.000); however, detailed analysis revealed significantly worse survival only in stage IIIC (10-year OS for IIIC vs IIIA+B, 35 vs 88%, p=0.001), while the difference between

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of BUON

ISSN

1107-0625

e-ISSN

—

Svazek periodika

19

Číslo periodika v rámci svazku

n. 3

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

5

Strana od-do

"p. 775-779"

Kód UT WoS článku

000342963300027

EID výsledku v databázi Scopus

—